The Role of Mitochondria ATP-sensitive Potassium Channel in Cardioprotection by Everton, Ksenia Andrukhiv
Portland State University 
PDXScholar 
Dissertations and Theses Dissertations and Theses 
5-13-2008 
The Role of Mitochondria ATP-sensitive Potassium 
Channel in Cardioprotection 
Ksenia Andrukhiv Everton 
Portland State University 
Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds 
 Part of the Biology Commons 
Let us know how access to this document benefits you. 
Recommended Citation 
Everton, Ksenia Andrukhiv, "The Role of Mitochondria ATP-sensitive Potassium Channel in 
Cardioprotection" (2008). Dissertations and Theses. Paper 5829. 
https://doi.org/10.15760/etd.7700 
This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and 
Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more 
accessible: pdxscholar@pdx.edu. 
THESIS APPROVAL 
The abstract and thesis of Ksenia Andrukhiv Everton for the Master of Science in 




Keith Garlid, Chair 
 
Todd Rose'nstiel 
Mich urphy, Chair 
Department of Biology 
ABSTRACT 
An abstract of the thesis of Ksenia Andrukhiv Everton for the Master of 
Science in Biology presented on May 13, 2008. 
Title: The role of mitochondrial ATP-sensitive potassium channel in 
cardioprotection. 
Mitochondrial ATP-sensitive potassium channel (mitoKArP) has been 
suggested to be the mediator of cardiac preconditioning. All of the diverse 
pharmacological and physiological agents that open mitoKArP provide 
protection against ischemia-reperfusion injury. Some investigators have 
pointed out that some of these mitoKArP channel openers also inhibit succinate 
dehydrogenase (SDH), complex II of the electron transport chain. Based on 
this observation they suggest that it is the inhibition of SDH, and not the 
opening of mitoKArP channel, that mediates the observed cardioprotection. In 
this study, I examined four chemically distinct and unrelated pharmacological 
agents, diazoxide, 3-Nitropropionic Acid (3-NPA), Protein Kinase G (PKG), 
and 4'ERACK, all of which have been shown to open mitoKArP, to demonstrate 
that the said cardioprotective effect mediated by mitoKArP is entirely 
independent of SDH. Light scattering technique was utilized to measure the 
state of mitoKATP (open/closed) by measuring mitochondrial volume. An 
electrode that measures oxygen concentration was utilized to measure 
mitochondrial respiration. The results of this study confirm that two of the 
drugs, diazoxide and 3-NPA, inhibit succinate-supported respiration in high 
doses (IC50 = 140µM and IC50 = 1.05mM, respectively). Both of these drugs, 
however, do not inhibit succinate-supported respiration at the concentration 
necessary to open mitoKATP (30µM and 1 0nM, respectively). PKG and 
4Je:RACK, the other two mitoKATP openers tested in this study, do not inhibit 
succinate-supported respiration at any concentration tested. These results 
support the hypothesis that potassium channel openers mediate 
cardioprotection through the opening of mitoKATP and not through the inhibition 
of SDH. 
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1. Introduction and Literature Review 
1.1 Heart Attacks and Infarct 
Heart attacks and their associated complications are the number one 
cause of death in the United States and worldwide. According to the 
American Heart Association there are over a million new and recurrent 
coronary attacks per year, and of these about 38 percent will result in death 
[1 ]. In addition, World Health Organization reported that acute myocardial 
infarction is the leading cause of death throughout the world in both men and 
women. During coronary thrombosis, commonly associated with 
atherosclerotic plaque in blood vessels, blood flow through the circulatory 
system is obstructed resulting in lack of nutrients and oxygen to the heart. 
Prolonged lack of nutrition may lead to tissue death, also known as infarction. 
Infarction and other known damage-causing aspects of a heart attack are 
induced by apoptotic and necrotic cell death mechanisms. This tissue 
damage is irreversible and begins within approximately 20 minutes of 
occlusion. Because infarcted tissue cannot regenerate and thus permanently 
decreases the size of functional cardiac tissue, return of blood flow should be 
accomplished as soon as possible [2]. 
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1.2 Normoxic Mitochondria 
Mitochondria are highly abundant eukaryotic organelles that have been 
essential to the evolution of complex organisms and are the site of aerobic 
respiration. They are bound by two specialized membranes (Figure 1) that 
together create two mitochondrial compartments: intermembrane space 
(between the two membranes) and the internal matrix (within the inner 
membrane). The matrix is the site of the citric-acid cycle and the highly 
convoluted inner membrane is the site of oxidative phosphorylation and the 
locus of mitochondrial ATP-sensitive potassium channel (mitoKATP). The 
outer membrane contains large numbers of integral proteins called porins, 
which form large aqueous channels through the lipid bilayer making it highly 
permeable to molecules of 5000 daltons or less. The inner membrane, on 
the other hand, is highly selective and largely impermeable to ions. 
Permeability to ADP, ATP, substrate anions and to Na+, K+ and Ca2+ is 
mediated largely by specific channels and carriers. A tight proton-
electrochemical gradient is maintained across this membrane in order to 
support the mechanism of ATP synthesis. The electron transport chain and 
ATP synthase are located within the inner membrane, which has a large 
surface area due to its cristae (or folds) in order to support these 
mechanisms. 
Proper function of the heart requires a large amount of cellular energy 
and over 90% of cardiac metabolism is aerobic [3]. In order to maintain this 
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metabolism, heart cells have a high oxidative capacity. It has been estimated 
that 25-35% of total cardiomyocyte volume is occupied by mitochondria [4]. 
About two-thirds of the ATP hydrolyzed by these mitochondria is utilized in 
the contractile apparatus of the heart, while the remaining is used in active 
transport in order to maintain ion balance, especially by sarcoplasmic 
reticulum Ca2+ -ATPase and the sarcolemmal Na+/K+ -ATPase [3]. In addition 
to being the site of the electron transport chain and the citric acid cycle, the 





Figure 1. Internal structures of mitochondria (modified from 
http://www.cartage.org). 
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1.3 lschemia-Reperfusion Injury 
During cardiac ischemia, blood flow to the heart decreases or stops 
completely, thus oxygen delivery to the mitochondria by and large ceases. 
The citric acid cycle is arrested and therefore no energy is available from 
oxidative phosphorylation. Non-esterified fatty acid levels rise leading to an 
accumulation of cytoplasmic NADH resulting in a severalfold rise in 
NADH/NAD ratio [3]. For several minutes after the arrest of oxidative 
phosphorylation levels of ATP may be maintained by glycolysis. Glycolysis, 
however, is unable to meet the demand of the beating heart for ATP for more 
than a few minutes [5]. In addition, after 30 minutes, lactate accumulates in 
the cell and cytospasmic pH decreases to 5.5-6 resulting in inhibition of 
glycolysis [3, 6]. ADP levels increase rapidly, while ATP levels fall slowly to 
about 50% of [ATP] at normoxic conditions after 30 minutes of ischemia [7]. 
Sodium-hydrogen exchanger (NHE), although relatively quiescent under 
aerobic conditions, becomes activated by intracellular acidosis, causing the 
extrusion of H+ and the influx of the concomitant Na+ [8]. Due to low ATP 
levels the sarcolemmal Na+/K+ -ATPase and sarcoplasmic reticulum Ca2+ -
ATPase become non-functional and cytoplasmic [Na+] and [Ca2+] increase. 
Na+ increase causes the Na+/Ca2+ exchanger to work in reverse, which 
inbibits Ca2+ efflux or even enhances the Ca2+ influx [9, 1 0]. It has been 
reported that with prolonged ischemia NHE is inhibited by extracellular 
acidosis that eventually exceeds intracellular acidosis [11, 12]. Soon, the 
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mitochondrial electro-chemical gradient is almost entirely diminished resulting 
in a great depression of the mitochondrial membrane potential. When in this 
extreme state of stress mitochondria are likely to trigger necrosis (accidental 
cell death associated with membrane rupture} and apoptosis (programmed 
cell death}. 
Although it is essential to return blood flow to the heart in order to 
salvage the myocardium and preserve functionality of the organ, the process 
of reperfusion itself causes additional deleterious effects not observed during 
ischemia. This phenomenon is collectively referred to as ischemia-
reperfusion injury. When blood is reintroduced to an ischemic system, rapid 
washout of extracellular H+ reactivates NHE, resulting in further intracellular 
Na+ accumulation. Again, Ca2+ influx follows causing abnormally high 
intracellular Ca2+ concentration. When oxygen is reintroduced to the 
respiratory chain, ubiquinone can become partially reduced to 
ubisemiquinone. This can in turn react with oxygen to produce superoxide 
that is reduced to hydrogen peroxide by superoxide dismutase [5]. Hydrogen 
peroxide, in the presence of ferrous ions, will form the highly reactive hydroxyl 
radical through the Fenton reaction [5, 13]. These reactive oxygen species 
(ROS}, which immediately increase slightly above normal when the heart 
becomes ischemic and then dramatically upon reperfusion [14] are extremely 
damaging to mitochondrial proteins. ROS have direct effects on complex 1 
and complex 3 of the respiratory chain, as well as other iron sulphur proteins 
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[5]. In addition, ROS may cause oxidation of glutathione that may then form 
mixed disulphides with proteins, which in turn inhibit protein pumps [15, 16]. 
Overall, it is thought that the combined effects of ROS and Ca2+ overload are 
responsible for ischemia-reperfusion injury and determine whether the injury 
is reversible. In particular, mitochondrial injury by these agents may lead to 
the opening of mitochondrial permeability transition {MPT). 
1.4 Mitochondrial Permeability Transition 
The mitochondrial inner membrane barrier to diffusive ion fluxes is 
essential in order to maintain the chemiosmotic gradient necessary to drive 
ATP synthesis. During ischemia-reperfusion, several factors including matrix 
calcium overload, high oxidative stress, high phosphate and low ATP 
concentrations induce the opening of a non-selective pore in the inner 
mitochondrial membrane, referred to as mitochondrial permeability transition 
{MPT) or mitochondrial permeability transition pore. During reperfusion, 
when oxygen is introduced ROS are produced and, with Ca2+ overload that 
happens during ischemia, MPT opens. This step takes place within 1-2 
minutes and this delay enables postconditioning. Once open, MPT allows 
unselective passage of any molecule up to 1.5kDa across the membrane. 
This uncouples oxidative phosphorylation, by allowing unrestricted proton 
movement across the membrane. The consequence of this is not only 
prevention of ATP synthesis but rapid consumption (hydrolysis) of ATP by 
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reversing ATP synthase in a futile effort to re-establish the membrane 
potential [17]. Under these conditions the ionic and metabolic homeostasis of 
the mitochondria is disrupted and degradative enzymes such as 
phospholipases, proteases, and nucleases are activated. Irreversible 
damage will eventually occur and the cell will die via necrosis if MPT remains 
open [3, 5]. A single opening of MPT is enough to depolarize the organelle 
as described and will activate further MPT opening within the same 
mitochondrion. This fully open state will result in a huge influx of small 
molecules, after which osmotically responsible water will follow resulting in 
matrix swelling. Swelling ultimately results in the rupture of the outer 
membrane (inner membrane withstands swelling due to the unfolding of 
cristae) and release of proapoptotic molecules in the intermembrane space 
such as cytochrome c and apoptosis-inducing factor (AIF) [18, 19]. Both 
cytochrome c and AIF instigate apoptotic processes and lead to cell death 
[17-21]. 
1.5 lschemic Preconditioning 
lschemic preconditioning (IPC) is an experimental physiological 
phenomenon in which brief episodes of ischemia and reperfusion protect the 
heart against subsequent lethal ischemic insult [22]. In the process of 
preconditioning, a series of cell signaling events modify cellular components 
in a manner that reduces myocardial damage from the sustained ischemia-
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reperfusion event. The IPC mechanism results in reduced infarct size, 
attenuating the incidence and severity of reperfusion-induced arrhythmias 
and preventing endothelial cell dysfunction [23]. Several endogenously 
released agents are involved in cardioprotection that results from 
preconditioning and include: opioids, norepinephrine, free radicals, 
adenosine, and bradykinin [24, 25]. 
1.6 Modes of Protection 
In addition to ischemic preconditioning, several other modes of cardiac 
preconditioning have been described. (1) Calcium preconditioning (CPC) 
mimics IPC when calcium concentration increases briefly within the 
cardiomyocyte. Exogenous increase in calcium administered just prior to 
ischemia activates protein kinase C (PKC) and induces myocardial functional 
protection similar to IPC [26]. (2) Potassium channel openers (KCOs) result 
in cardiac preconditioning when administered prior to ischemia by increasing 
K+ conductivity [27]. (3) Inhibition of sodium/proton exchanger by agents 
such as cariporide ultimately prevents Ca2+ overload and unusual Na+ 
gradients when administered prior to ischemia and thus causes decreased 
cardiomyocyte damage [28, 29]. (4) lschemic post-conditioning describes a 
phenomenon in which the heart undergoes ischemia and reperfusion with no 
pretreatment of any kind. Shortly after reperfusion, however, the heart is 
subjected to cycles of ischemia and reperfusion, resulting in similar extent of 
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protection as IPC [30). 
1. 7 Cardioprotection by Potassium Channel Openers 
Grover et al discovered that two drugs capable of cardioprotection, 
cromakalim and pinacidil, were KCOs [27). Both were known vasodilators. 
The vasodilator activity of these agents was attributed to their ability to 
increase ATP-dependant K+ channel (KATP) conductance. In addition, there 
was electrophysiological evidence that indicated that both activated KATP 
channels in cardiac myocytes [31). Activation of K+ channels in smooth 
muscle cells leads to hyperpolarization and consequent action potential 
shortening [32]. Cardioprotective effects of cromakalim and pinacidil was 
reversed by glyburide (glybenclamide) [27], which has been shown to be a 
high affinity blocker of ATP-dependent K + channels [33). A variety of other 
KCOs were shown to be cardioprotective when administered prior to 
ischemia, including nicorandil, cromakalim, pinacidil, bimakalim, aprikalim, 
and P-1075 [27, 34-36]. These findings were consistent throughout different 
animal species [37-41 ]. Cardioprotective effects of all KCOs were reveresed 
by the blocker glyburide. 
1.8 M~toKArP Mediates Cardioprotection by KCOs 
Initially, it was believed that the cardioprotection afforded by KCOs 
was modulated via the sarcolemmal ATP-sensitive K+ channel (sarc~TP). 
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Potassium activation in the cell leads to hyperpolarization of the cell and 
subsequent action potential shortening. Hyperpolarization due to increased 
potassium conductance may bring the resting potential further from the 
threshold that activates calcium channels; inhibiting calcium influx and 
reducing ischemia. This view was significantly questioned when several 
experiments showed that cardioprotection is possible without action potential 
duration (APD) shortening [42-44]. Also, in 1991, Inoue et al identified an 
ATP-sensitive potassium channel in the inner mitochondrial membrane in rat 
liver through patch clamp experiments, and Paucek reconstituted and 
partially purified ATP-sensitive potassium channel that was sensitive to 
glibenclamide (K+ channel closer) from rat liver and beef heart mitochondria 
[45, 46]. A few years later, in 1996, work by Garlid et al put forth the 
hypothesis that it is the mitochondrial ATP-sensitive K+ channel (mitoKArP) 
that is responsible for the cardioprotective effects of KCOs and not sarcKArP 
[47]. This finding was based on several independent observations and 
explained the paradoxical finding that the action potential shortening in 
cardiac myocytes and cardioprotection through KCOs did not correlate. First, 
it was demonstrated that various KCOs opened mitoKArP in isolated 
mitochondria within their cardioprotective concentration range [47]. Second, 
sarcKArP was shown to be almost completely insensitive to diazoxide, a 
pharmacological agent with known cardioprotective properties, or 5-HD 
(5-hydroxydecanoate ), which blocks cardioprotection, while mitoKArP, 
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assessed in isolated mitochondria, is sensitive to both in the pharmacological 
dose range [4 7-49]. 
In 1997, Garlid et al [48] confirmed the mitoKArP hypothesis with the 
following findings: although both diazoxide and cromakalim (non-selective 
KCO) afforded similar levels of protection against ischemia-reperfusion injury, 
cardioprotection via cromakalim was accompanied by some action potential 
duration (APD) shortening, whereas no APD shortening was caused by 
diazoxide, the selective mitoKArP opener, demonstrating that diazoxide does 
not act via sarcKArP· Since this discovery, numerous laboratories have 
provided evidence to support the paradigm that mitoKArP, and not the 
sarcKArP, is the mediator of ischemic preconditioning and precondition by 
KCOs [50-55]. 
1.9 MitoKATP During Normal Conditions 
It is conceivable that mitoKArP evolved in order to provide a mode of 
cardioprotection, via IPC. However, this protein appears to exist in all 
mammalian species studied, including several that are not susceptible to 
ischemic heart disease [56]. Thus, it has been proposed that mitoKArP plays 
a role in cardiac physiology during normal conditions and protection against 
ischemia happens to be a beneficial byproduct. 
1.9.a MitoKATP in normal cell signaling 
There is some evidence that mitoKArP plays a role in normal cell 
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signaling process that leads to cell growth. It has been shown that ouabain, a 
ligand of Na/K-ATPase, stimulates mitochondrial ROS production via a Ras-
dependent pathway [57]. Among others, this ROS production is an element 
that the ouabain and the cardioprotection pathways share in common, 
thereby linking the two [58]. Furthermore, it has been shown that the ouabain 
signaling pathway is blocked not only by ROS scavengers but also by 5-HD -
increasing support for the hypothesis that the two pathways are linked [58]. 
The interplays among these pathways in cardiomyocytes lead to changes in 
the expression of several genes. [56]. 
1.9.b MitoK.A TP opening in high work state - maintenance of positive 
ionotropy 
During high work state, when the cardiomyocyte is undergoing high 
rates of ATP production and consumption, electron transport is high and the 
membrane potential significantly decreases. As Garlid explains in his review 
[56], this observation is identical to any other battery system, where drawing 
high currents ill decrease the output voltage. This decrease in membrane 
potential will result in the contraction of the mitochondrial matrix (because 
decrease in membrane potential decreases the influx of ions and the 
osmotically obligated water that enters with them), and the expansion of the 
inter-membrane space (IMS). However, mitoKATP, when open, provides a 
parallel potassium conductance that counteracts this matrix contraction, 
resulting in the preservation of matrix and IMS volume. IMS preservation is 
critical in maintaining the association of VDAC (voltage-dependent ion 
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channel), which controls outer membrane permeability to ADP and ATP, and 
creatine kinase. Creatine kinase phosphorylates creatine, using ATP 
produced by the mitochondrial ATPase, creatine phosphocreatine and ADP. 
The high-energy phosphate bond of phosphocreatine has more energy than 
the bond of ATP, 10,300 calories per mole in comparison with 7,300. 
Phosphocreatine presumably gets shuttled into the cytosol through VDAC 
and holds enough energy to reconstitute the high-energy bond of ATP. 
Therefore, this system provides an energy store in the cell and is incredibly 
important in the heart, where high work states are very frequent [56]. It has 
been proposed that endogenous signals open mitoKATP during high work state 
in order to maintain matrix volume and the association between VDAC and 
creatine kinase. Garlid and colleagues [56] tested the hypothesis that 
mitoKATP opening is required for the positive inotropic response (increased 
contractility) by testing mitoKATP inhibitors in this system. Consistent with the 
hypothesis, these authors found that mitoKATP blockers (5-HD and TPP+) 
prevented inotropic response indeed. 
1. 10 MPT and mitoKATP 
lschemic preconditioning as well as preconditioning by KCOs reduces 
MPT opening and decreases infarct size [59-61]. In order to describe the 
mechanism that acts in this situation, Karge et al [62] simulated ischemia in 
isolated mitochondria and caused MPT opening by exposing them to high 
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Ca2+ and phosphate. Diazoxide (mitoKATP channel opener) and phorbol 12-
myristate 13-acetate (PMA, pharmacological agent that activates Protein 
Kinase C (PKC) by mimicking diacylglycerol - a physiological PKC activator) 
both blocked MPT opening and the release of cytochrome c, while 5-HD 
(mitoKATP channel closer) reversed this effect [63]. These results supported 
the hypothesis that the protective mechanism of blocking MPT operates 
through PKC [49]. Working with genetically modified mice with cardiac-
specific expression of recombinant PKCs, Baines et al [64] demonstrated that 
PKCs activity inhibited MPT opening in heart mitochondria. Other studies 
have demonstrated that inhibition of PKC by pharmacological agents blocks 
protection via IPC [65]. Also, hearts from PKCs knock-out mice do not exhibit 
protection by IPC [66]. In addition to PKCs involvement Kim et al [67] 
suggested that MPT inhibition operated through a guanylyl cyclase-
dependent signaling pathway by showing that cyclic GMP ( cGMP) prevented 
MPT opening. Interestingly, it was shown that mitochondria swell in K+ 
medium after addition of Protein Kinase G ( PKG) and cGMP [68]. This 
swelling is highly indicative of a potassium channel opening suggesting that 
PKG + cGMP cause mitoKATP to open. In addition, KT5823, a specific 
inhibitor of PKG blocked this effect, while mitoKATP specific opener, diazoxide, 
reversed inhibition by KT5823 [68]. In 2006 our laboratory demonstrated the 
mechanism by which mitoKATP opening inhibits MPT activation in heart, liver, 
and brain mitochondria. In agreement with previous experiments, this 
15 
mechanism utilizes PKG and PKCE as obligatory intermediates [49]. Upon 
activation in this process, mitoKATP increases ROS. Interestingly, ROS (in this 
experiment H2O2), in concentrations at least 50 times smaller than those that 
induce MPT opening provides protection from MPT opening via PKCE 
independent of mitoKATP, suggesting that small amounts of ROS may be 
protective [49, 69]. These data suggest that mitoKATP opening protects the 
heart from ischemia-reperfusion by inhibiting MPT and thus cell death by 
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Figure 2. (Modified from [49]) 
The cardioprotective signaling pathway in mitochondria. Active PKG from the 
cytosol, which cannot cross the outer membrane of the mitochondria, 
phosporylates an unknown protein at the surface of the mitochondria. This 
protein presumably activates PKCc1, that is thought to be bound to the outer 
surface of the inner mitochondrial membrane. Then, PKCc1 phosphorylates 
and thus opens mitoKATP, resulting in an influx of potassium ions. Matrix 
potassium increase results in matrix alkalinization and eventually a small 
increase in matrix H2O2• This increase in H2O2 activates PKCc2, causing the 
inhibition of MPT. PKCc1 and PKCc2 are identical enzymes localized in 
different pools within the pathway. It is also known that this modest increase 
in H2O2 activates a number of other kinases. 
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1.11 Mechanism of Cardioprotection Induced by MitoKATP 
The primary function of mitoKATP channels is to regulate mitochondrial 
volume [70, 71 ]. It is absolutely essential to maintain appropriate 
mitochondrial matrix volume, and thus vesicular integrity, in the face of the 
ever changing environment of the inner membrane space, with numerous 
ions, molecules, and water leaving and entering the inner membrane space. 
This is largely accomplished by the regulation of K+ transport, via diffusion 
and via mitoKATP [70, 71 ]. Diffusive uptake of K+ is exponential with voltage 
and is thus highly sensitive to the mitochondrial membrane potential. K+ 
uptake is followed by uptake of phosphate (Pi) on the Pi/OH· exchanger, 
followed by osmotically obligated water [72]. On the other hand, K+ leaves 
the inner membrane space via the K+/H+ antiporter, again, followed by water. 
In this way, the balance between the ion (and water) influx is balanced by the 
activity of K+/H+ antiporter. During ischemia, the mitochondrial membrane 
potential is low, mitochondria depolarize due to anoxia and mitochondrial 
matrix contraction results. As a result, inner membrane space architecture 
gets highly distorted, and ATP hydrolysis is accelerated due to disruption of 
mitochondrial creatine kinase [71]. Increased K+ conductance through the 
opening of mitoKATP may help to maintain inter-membrane space architecture 
and slow down the hydrolysis of ATP, allowing the use of creatine as 
substrate upon reperfusion [71]. 
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1.12 MitoKATP in Other Tissues 
MitoKATP has been shown to provide protection in pancreatic beta-cells 
by preventing the onset and development of diabetes in rats. The selective 
mitoKATP opener, diazoxide, inhibited apoptosis by directly opening mitoKATP 
and this effect was completely abolished by 5-HD [73]. As in the heart, 
ischemia-reperfusion injury may also lead to apoptosis in the brain [74]. 
Mitochondria in the brain contain seven times more mitoKATP channels then 
heart mitochondria [75]. There is support that mitoKATP protects the brain 
against ischemia reperfusion injury in vivo models: diazoxide preserves 
neuronal-vascular function after cerebral ischemia in piglets [76] and induces 
protection induced by hypothermic circulatory arrest in canine models [77], 
both effects were reversed by 5-HD. A study in cultured cerebellar granule 
neurons, where H2O2 was used to simulate neuronal apoptosis, suggested 
that mitoKATP provides neuroprotection by preserving mitochondrial inner 
membrane potential [78]. 
1.13 The Argument 
Diazoxide and 5-HD have become synonymous with mitoKATP opening 
and closing, respectively. The paradigm that mitoKATP is the mediator of 
preconditioning via KCOs has been questioned by a number of investigators 
[79-83]. In particular, it has been proposed that diazoxide and 5-HD mediate 
cardioprotection independently of mitoKATP [79, 81, 83]. This controversy has 
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be intensified by the lack of a molecular identity for mitoKATP· Throughout the 
last six years or so, several investigators, most recently Minners [79] have 
concluded that cardioprotection by diazoxide is afforded by respiratory chain 
inhibition [81, 82, 84]. In fact, it has been known for almost forty years that 
high doses of diazoxide significantly decrease mitochondrial respiration by 
inhibiting succinate-dehydrogenase (SDH) [85]. These investigators fail to 
take into account the differences in the concentrations of this drug in both 
circumstances. Diazoxide inhibits SDH at high concentrations, while 
cardioprotection is achieved in much lower doses. In fact, it is very 
reasonable to suppose that most hydrophobic drugs, such as DZX, when 
used in very high concentrations will embed themselves into the membrane 
and cause physiological changes. It is also important to point out that these 
arguments focus on diazoxide, ignoring the fact that many other mitoKATP 
openers provide cardioprotection without inhibiting the respiratory chain. 
The same three laboratories proposed that 5-HD, which is a hydroxy 
derivative of decanoate, antagonizes the effect of diazoxide by being 
metabolized like other medium-chain fatty acids in the heart. Again, 
metabolism of 5-HD is already know from previous work [86]. 5-HD has a 
very short (7 minute) biological half life in dogs [86] and blocks 
cardioprotection when given 2 minutes, but not 8 minutes, before IPC [87]. 
These authors suggested that the short half life is due to 5-HD being 
converted to 5-HD-CoA by mitochondria in the presence of ATP and CoA 
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[56]. Those that have proposed this explanation for cardioprotection suggest 
that 5-HD blocks cardioprotection by interfering with normal cardiac 
metabolism, although do not explain how this may be. Again, these 
arguments do not explain why glibenclamide [48] and HMR1098 [88] block 
cardioprotection by diazoxide. 
MitoKATP openers diazoxide, 3-NPA, 'I'ERACK, and PKG will be utilized 
in our experiments. Therefore, they are briefly discussed in sections below. 
1.14 3-NPA 
3-Nitropropionate (3-NPA) is a widely distributed plant and fungal toxin 
first identified by Morris et al in 1954 as the primary toxic agent of lndigofera 
endecaphylla [89, 90]. It is produced on moldy crops such as sugarcane and 
peanuts and causes severe neurological disorders in humans when 
consumed in sufficient amounts [91-93]. 3-NPA is said to be a suicide 
Figure 3. 3-NPA (left), in its carbanion form, is 
isoelectic with succinate (right). 
inhibitor of succinate 
dehydrogenase (SDH), 
associated with the 
c____ ______________ ___J tricarboxylic acid cycle and 
complex II in the respiratory chain. Alston et al demonstrated that the dianion 
form of 3-nitropropionate is the inhibitory form [90]. The carbanion form of 
this compound is isoelectric with succinate (Figure 3), SDH substrate [90], 
and reacts progressively with N-5 of the covalently bound flavin to form a 
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covalent adduct [94] (Figure 4 ). This binding is irreversible [90, 94]. 
Chemical preconditioning with 3-NPA has been shown to have a protective 
effect against ischemic hypoxic neuronal damage in vitro [95-97]. 
Interestingly, the symptoms of 3-NPA toxicity closely resemble those of 
Huntington's disease and thus provide a research model for understanding 
the mechanisms of Huntington's [98]. Several findings show that the type of 
neuronal death induced by 3-NPA is dose-dependent [99]. In vivo and in rat 
hippocampal cell cultures, intermediate doses of the compound result in 
apoptosis [100], while high doses led to NMDA-receptor dependent 
excitotoxic cell death. It is speculated that dependent on its concentration 3-
NPA can induce three different cellular responses: tolerance (preconditioning) 
[96], apoptosis, or necrosis. 3-NPA addition caused a pronounced decrease 
in [creatine phosphate/creatine] and a fall in [ATP/ADP] as well as 
[GTP/GDP] [98]. It has been well established that reductions in energy 
metabolism are neuroprotective. However, it is unlikely that preconditioning 
via low doses of 3-NPA is an example of this phenomenon because 3-NPA 
preconditioning is evident much later (several days) after normal ATP levels 
and SDH activity have been reestablished [96]. It may therefore be 
concluded that inhibition of SDH is not the mechanism by which 3-NPA is 
protective in the brain. 
Riepe et al hypothesized that ATP-sensitive potassium channels may 
be responsible for the effect of administrating sub-lethal doses of 3-NPA after 
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conducting electrophysiological studies on rat hippocampal slices [101 ]. 
Further investigation and in situ studies demonstrate that neuroprotection via 
3-NPA was abolished by administration of glybenclamide and 5-HD [102]. 
Additionally, 3-NPA administration resulted in mitochondrial depolarization 
and these effects were also blocked by 5-HD [102]. These results suggest 
that mitoKATP plays a significant role in 3-NPA preconditioning in the brain. 
Several studies also suggest that 3-NPA protects the heart from 
ischemia-reperfusion injury. Experiments on a Langendorff apparatus 
demonstrated that 3-NPA provides significant cardioprotection [103]. Ockaili 
and coworkers demonstrated that 3-NPA induces an immediate and delayed 
cardioprotective effect in the heart as indicated by a significantly decreased 
infarct size compared with control animals. The mitoKATP selective opener, 5-
HD, abolished both the early and the delayed cardioprotective effects when 
administered before ischemia-reperfusion [104]. This evidence indicates that 
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Figure 4. Proposed mechanism by which 3-NPA irreversibly deactivates 
succinate dehydrogenase (on the left) compared to the cyclic mechanism by 
which SDH converts succinate into fumarate and supplies electrons into the 
electron transport chain (ETC) (Modified from [94]. 
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1.15 Diazoxide 
Diazoxide (3-methyl-7-chloro-1,2,4-benzo- thiadiazin-1, 1 dioxide) 
(figure 5) is a synthetic drug that has been used as a diabetogenic agent, by 
Figure 5. Molecular 
structure of diazoxide 
suppressing of insulin secretion in vivo and in 
vitro [85]. It is the most potent beta-cell KArP 
channel opener known and it successfully 
hyperpolarizes the beta-cell, thereby inhibiting 
insulin secretion [105] and by preventing 
~--------~ apoptosis in pancreatic beta-cells of pre-diabetic 
and diabetic rats [73]. Diazoxide is also used inter-venously to treat severe 
hypertension as it relaxes arteriolar smooth muscle [106]. Both of these 
clinical applications of diazoxide were widely used before the discovery of 
ATP-sensitive potassium channels. In 1969, Schafer et al reported that 
diazoxide inhibited succinate dehydrogenase (SDH), complex II of the 
electron transport chain in isolated rat liver mitochondria and beef heart 
submitochondrial particles [85]. Their findings demonstrated that in high 
concentrations, diazoxide strongly inhibits succinate-supported respiration but 
not NADH-linked substrate oxidation. Belyaeva et al and Szewczyk et al 
reported that diazoxide (and other KCOs) also act on respiring mitochondria 
[107, 108]. Their reports suggested that diazoxide effects on mitochondria 
are pharmacologically irrelevant because its effect was very weak at 
concentrations much higher than K1,2 values observed with sarcKArP [109]. In 
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1996 Garlid et al reported that diazoxide was a very potent activator of the 
ATP-sensitive potassium channel in intact mitochondria and proteoliposomes 
containing recontituted mitoKATP [47]. No effect was observed on uninhibited 
potassium flux, likely explaining the low potencies that Szewczyk and 
Kelyaeva reported [4 7]. Due to the observation that diazoxide opens 
mitoKA TP channel at a concentration that has no effect on the sarcKATP 
channel, focus shifted from sarcKATP to mitoKATP channel as mediator of 
cardioprotection [4 7]. 
1. 16 'PeRACK 
'I'sRACK is a selective PKCs (Protein Kinase C epsilon) activator 
peptide. It is derived from PKCs and is eight amino acids long [HDAPIGYD]. 
PKC (Ca2+-dependent protein kinase) is a serine/threonine kinase found 
abundantly in many different cell types. PKCs is one PKC isozyme (one of 
six) that is constitutively present in heart mitochondria [11 O]. There are many 
reports that PKCs activation plays a critical role in transmitting a signal that 
induces cardioprotection [68, 111-114]. Baines et al [64] and Karge et al [63] 
have shown that PKC activation is able to inhibit MPT opening. Costa et al 
[49] demonstrated that 'I'sRACK provides cardioprotection through mitoKATP 
through the inhibition of MPT. This finding that 'I'sRACK provides 
cardioprotection by mimicking ischemic preconditioning has been 
demonstrated by a number of laboratories [111, 113, 115, 116]. 
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1.17 PKG 
cGMP-dependent protein kinase (PKG) is an abundant 
serine/threonine kinase activated by cyclic GMP ( cGMP), in fact, it is the 
major intracellular receptor of cGMP [117]. It is present in high amounts in 
platelets, cerebellum, smooth muscle, cardiac muscle, hippocampus, dorsal 
root ganglia, neuromuscular end plate, and the kidney vasculature. Low 
levels have been detected in granulocytes, vascular endothelium, 
chondrocytes, and osteoclasts. PKG phosphorylates a number of 
physiologically relevant proteins involved in regulating the contractile activity 
of smooth muscle cells, regulation of cell differentiation and proliferation, 
inhibition of platelet aggregation and apoptosis [118, 119]. Han et al [120] 
first suggested that PKG is involved in the signaling pathway that induces 
cardioprotection via ischemic preconditioning in rabbit ventricular myocytes. 
In their experiments, PKG was found to be responsible (at least in part) to 
phosphorylation and activation of KATP channels. Selective PKG inhibitors 
abrogated any effects [120]. Oldenburg et al [121] studied mitochondrial 
ROS generation by bradykinin and concluded that PKG activation (in their 
case by ROS) triggers preconditioning by opening mitoKATP· In order to 
uncover the mechanism by which PKG acts on mitoKATP, Costa et al [68] 
conducted light scattering experiments which demonstrated that active PKG 
(and cGMP necessary to activate it) is indeed necessary to open mitoKATP in 
vitro, and KT5823, a specific PKG inhibitor, blocked this effect. Interestingly, 
the inhibition of PKG by KT5823 was reversed by the addition of the specific 
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mitoKATP opener diazoxide [68]. In addition, PKG-induced effect was 
reversed by 5-HD (selective mitoKATP inhibitor) [68]. These investigations 
suggest that active PKG activates mitoKATP by indirect phosphorylation, and 
that this phenomenon is not limited to cardiomyocytes and has been 
observed in brain and liver mitochondria [68]. 
1.18 Overall Hypothesis 
Several investigators have suggested that cardioprotection afforded by 
ischemic preconditioning is not mediated through mitoKATP but results from 
the inhibition of Complex II of the electron transport chain, succinate 
dehydrogenase. In this study, I have examined four chemically distinct and 
unrelated pharmacological agents, all of which have been shown to open 
mitoKATP, to demonstrate that the said cardioprotective effect mediated by 




Male rats of the Sprague-Dawley variety were used in all experiments. 
The rats were about 2 months old and weighed 225-2499. They were 
housed two per cage in a 24°C room and were fed and watered ad libitum. 
Diet consisted of standard rodent formula chow from labDiet. All procedures 
involving animals are in accordance with the American Physiological Society 
"Guiding Principles in the Care and Use of Animals" and was approved by 
Institutional Animal Care and Use Committee at Portland State University. 
2.2 Mitochondrial Isolation 
One or two rats were anesthetized with CO2 for 20-30 seconds and 
immediately decapitated. An incision into the chest cavity was made using 
surgical scissors and hearts were quickly removed and rinsed in ice-cold 
Buffer A (250mM sucrose, 10mM HEPES pH 7.2, 5mM K-EGTA, and 
1 mg/ml fatty-acid free BSA). Hearts were squeezed manually until most of 
the blood was removed. The hearts were then finely minced in Buffer A 
containing 1 mg/ml protease (Nagarse) for approximately 40 seconds. The 
suspension was then diluted with Buffer A and homogenized with a motorized 
Teflon pestle until the homogenate looked uniform (about 45 seconds). The 
entire homogenate was then divided equally into two 30ml plastic tubes and 
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diluted with additional Buffer A to bring the volume just shy of the top of the 
tubes. These were then spun at 1700g for 3 minutes. The resulting 
supernatant containing the mitochondria was decanted into clean, ice-cold 
tubes and further centrifuged at 9000g for 5 minutes. Pellet from the first spin 
containing blood cells and cellular fractions was discarded. The pellet from 
the second spin was carefully resuspended in Buffer B (Buffer A minus BSA) 
and centrifuged again for 4 minutes at 23009. The resulting supernatant was 
centrifuged one more time to pellet the isolated mitochondria at 9000g for 5 
minutes. This final mitochondrial pellet was resuspended in about 200µL of 
Buffer B and stored on ice. 
2.3 Protein Measurement 
All protein was measured in Thermo Spectronic Genesys 20 using the 
Biuret Method first described by Gornall [122]. 
2.4 Measurement of Mitochondrial Volume 
Mitochondrial matrix volume was measured by light scattering 
technique as first described by Beavis [123]. Mitochondria respond to 
osmotic pressure of their environment by taking up, or pumping out of water. 
When osmolarity outside the mitochondria increases and salt begins to enter 
the mitochondrial membrane - obligated water follows resulting in 
mitochondrial matrix swelling; shrinking occurs due the reverse. When 
mitoKATP is opened, regardless of the cause, potassium ions and water flow 
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into the matrix and swelling is observed. Matrix contraction is observed when 
mitoKArP is closed. Therefore, mitochondrial swelling and shrinking in a 
potassium rich medium is indicative of the state of mitoKArP· The light 
scattering technique utilizes a Brinkmann PC 700 colorimeter light probe 
fitted with a 520 nm filter. A small mirror about 1 cm below the light source 
reflects the light that has not been absorbed back into the system. Increase 
in matrix volume is accompanied by a decrease in the intensity of light 
scattered by the suspension, because as mitochondria swell, they absorb 
more (and therefore scatter less) light [123, 124]. The probe is normally 
immersed in 2 ml of assay medium and mitochondria protein (0.1 mg/ml) 
suspension, which is constantly stirred and maintained at 30°C. Absorbance 
is measured and quantified [123] using a computer program developed in our 
laboratory. It is based on the principle that reciprocal absorbance (A) of the 
mitochondrial suspension (proportional to matrix volume, which depends on: 
medium osmolality, matrix solute content, and the concentration of 
mitochondria [123], when corrected for the extrapolated absorbance at infinite 
protein concentration is linearly related to the matrix volume. This 
absorbance is then converted to beta(•), which corrects for variations in 
protein concentraion: 
where• is the machine constant (0.25 in the case of our apparatus), A is 
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absorbance, Pis mitochondrial concentration (mg/ml), and Ps (equals 
1 mg/ml) is introduced to make • a scaled dimensionless quantity (123]. 
Conversion to • allows comparison of multiple experiments. The light 
scattering assay medium contains 120mM KCI, 10mM HEPES (pH 7.2), 
0.1mM EGTA, 10mM succinate, and 5mM phosphate. Rotenone (5µM), 
which inhibits complex I of the electron transport chain and the reverse 
electron transfer from complex II to complex I as well as oligomycin (0.67µM), 
which inhibits ATP synthesis by the ATPase and consequent decrease in 
membrane potential are also added to all assay media. 
MitoKATP openers and closers were added to the assay media in 
appropriate concentrations to determine their effect on mitoKATP (swelling 
indicates open channel, shrinkage - closed). 
2.5 Measurement of Mitochondrial Respiration 
Respiration was measured using a Yellow Springs Instruments oxygen 
electrode (Clark polarographic sensor), model 53. Electrode is connected to 
a chamber containing 2ml of respiration solution of constant temperature 
(25°C). At normal conditions this chamber contains a set amount of oxygen 
(960ng atoms O in 2ml at 25°C). After the addition of respiring mitochondria, 
the oxygen amount decreases and this linear rate is plotted on the computer 
that is connected to the electrode. Chemicals were added to the assay 
chamber containing the assay medium and mitochondria and their effect on 
respiration were observed. Respiration assay medium contains: 11 0mM 
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sucrose, 10mM HEPES pH 7.2, 2.5mM Pi, 0.1mM EGTA, 0.5mM MgCl2, and 
1 0mM succinate. 5µM rotenone was also added to each run in order to 
inhibit Complex I of the electron transport chain. 
2.6 Solutions 
All solutions were made with deionized water from Millipore Synergy 
185. For contents of each medium please refer to sections above. 
2. 7 Chemicals and Reagents 
Most chemicals were purchased from Sigma Chemical Co. except for 
PKG (Promega), cGMP (EZ Biolabs), and 'l'cRACK (EZ Biolabs). 
2.8 Data Analysis 
All data analysis was done using the program ORIGIN by Microcal. 
Respiration data were analyzed as follows. Each dose was assessed in an 
independent run. Mitochondria and rotenone were added immediately (at 
time 0), 100 seconds later CCCP (carbonyl cyanide m-chloro phenyl 
hydrazone, a mitochondrial uncoupling agent) (35µM) was added, 100 
seconds after that the appropriate drug was added. The CCCP alone and 
CCCP+drug rates were converted into (ng atoms oxygen)*(min-1)*(mg protein-
1). Then a ratio of (CCCP + drug) rate/(CCCP) rate was calculated and 
multiplied by 100% in order to calculate"% of control". Thus, each individual 
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run had its own no drug control to account for slight differences in pipetting, 




Diazoxide opens mitoKA TP at 30µM in rat heart mitochondria. Figure 
6 demonstrates the swelling that is associated with mitoKATP opening due to 
the presence of diazoxide. This opening is reversed by 5-HD. Diazoxide 
concentrations above 1 mM inhibit succinate-supported respiration by 75% in 
rat heart mitochondria, IC50 = 140µM (Figure 7). 
3.2 3-NPA 
3-NPA opens mitoKA TP at 1 OnM in rat heart mitochondria (Figure 8). 
This opening was reversed by 5-HD. 3-NPA inhibits succinate supported 
respiration, IC50 1.05mM. 
3.3 PKG 
PKG + cGMP do not inhibit succinate-supported respiration below 96% 
of full function in the dose range tested. Figure 1 Ob demonstrates the raw 




'PsRACK does not inhibit succinate-supported respiration below 92% 








Diazoxide Opens MitoKATP 




Figure 6. Light scattering assay results demonstrating that diazoxide (30µM) 
opens mitoKATP in KCI medium. 5-HD reverses this opening in the presence 
of ATP (n = 4). 
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Figure 7. Respiration assay results demonstrating that diazoxide inhibits 
succinate-supported respiration. Hill slope = -2.4, IC 50=11 OµM, sucrose 






3-NPA Opens MitoKArP 30° 
f&fll! NDMl'lhffrtr\1-ATP + 1 OnM 3-NPA 
allfJ11NAal'ha'NIW'll.LM'-ATP + 10nM 3-NPA 
- No additions 
0.18---------------------
0 30 60 90 120 
Time (sec) 
Figure 8. Light scattering assay demonstrating that 3-NPA (1 OnM) opens 
mitoKATP in isotonic KCI medium, in the presence of succinate, rotenone, and 
oligomycin. This effect is reversed by 5-HD (n = 1 ). 
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Figure 9. Respiration assay demonstrating that 3-NPA inhibits succinate-
supported respiration in sucrose medium, in the presence of rotenone. Hill 
Slope= -1.1, IC 50 = 1.05mM (n = 4). 
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Figure 10a. Respiration assay demonstrating that PKG+ cGMP do not 
inhibit succinate-supported respiration in sucrose medium, in the presence of 
rotenone (n=3). 
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Figure 1 Ob. Raw traces from respiration assay demonstrating that PKG + 
cGMP do not inhibit succinate-supported respiration in sucrose medium, in 
the presence of rotenone (n=3). (1 unit = amount of kinase required to 
incorporate 1 pmol of phosphate into the test heptapeptide (RKRSRAE) per 
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Figure 11 a. Respiration assay showing that 'l'eRACK does not inhibit 
succinate-supported respiration in the tested range. Sucrose medium, in the 
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Figure 11 b. Raw traces from respiration assay demonstrating that 'l'sRACK 
does not inhibit succinate -respiration in the tested range. Sucrose medium, 
in the presence of rotenone (n=3). 
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4. Discussion 
In 1986, Murry et al. described a paradoxical phenomenon whereby 
brief ischemic insults reduce damage to the heart caused by a subsequent, 
prolonged ischemic event [22]. Since 1989, when Grover et al. suggested 
that opening KATP channels protects the heart from ischemia-reperfusion 
injury, there has been a growing interest in investigating the details of this 
mechanism. Although the classical sarcolemal KATP channel was though to 
be the mediator of this cardioprotective pathway [125-127], compounding 
evidence suggested that the mitochondrial KATP channel, located in the inner 
mitochondrial membrane, was responsible for this effect [45, 4 7, 54, 55]. 
Garlid et al demonstrated that it is the mitoKATP channel that is the site of 
action of all KATP channel openers [48]. This shift of paradigm has stirred a lot 
of debate as the details of this cardioprotective mechanism are investigated. 
Some of the difficultly in pinpointing the mechanism by which mitoKATP 
induces cardioprotection lies in the fact that molecular identity of this channel 
remains unclear. Indeed, what is known about mitoKATP comes largely from 
pharmacological investigation. SarcKATP channels have been molecularly 
defined as an octamer composed of four pore-forming inwardly-rectifying 
potassium (Kir6.1 and Kir6.2) subunits and four sulfonylurea receptors 
(SUR2A), which confer a regulatory role and a sensitivty of the channel to 
ATP and pharmacological regulators [128]. MitoKATP channels share some 
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pharmacological, and thus likely structural, properties with the classical 
sarcKATP counterpart. Both channels are activated by pinacidil and inhibited 
by glibenclamide [46, 48]. In order to study the mechanism of 
cardioprotection, which has been suggested to operate through mitoKATP, it is 
crucial to utilize specific activators and inhibitors of this channel. Obviously, it 
is also important to ensure that the specific pharmacological agents don't 
have effects on other, relevant systems. 
Diazoxide and 5-hydroxydecanoate have been utilized as a selective 
mitoKATP channel opener and closer, respectively. Several investigators, 
most recently Minners et al [79], have rejected the role of mitoKATP in 
cardioprotection on the basis that diazoxide (and 5-HD) effects that have 
been attributed to mitoKATP are actually due to these drugs' effects on 
mitochondrial respiration. Therefore, it was a goal of this study to investigate 
whether the observed effect can be attributed to respiratory inhibition instead 
of mitoKArP activity. 
It was reported almost forty years ago that at high doses diazoxide 
inhibits succinate dehydrogenase, complex II of the electron transport chain 
[85]. Indeed, all hydrophobic drugs including diazoxide (and pinacidil, 
another KArP channel opener) exhibit concentration-dependent inhibition of 
the respiratory chain. This is due to their tendency to embed in the 
hydrophobic membrane and cause a plethora of effects. This is further 
supported by the observation that diazoxide is not entirely specific to SDH 
[129]. The results of the current study strongly suggest that diazoxide inhibits 
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succinate-supported respiration at high doses (IC50 = 11 0µM) down to 30% 
respiratory activity at about 1 mM diazoxide (figure 7), as previously 
described. However, these concentrations are in excess of those necessary 
to open mitoKATP (figure 6). In fact, the K1,2 for diazoxide mitoKATP opening is 
merely 3µM (Garlid 1996). In our studies, 30µM diazoxide is used in light 
scattering assays in order to ensure complete channel opening. Even at this 
concentration, no significant respiratory inhibition is observed. 
At high concentrations 3-NPA acts as a suicide inhibitor of SDH by 
binding irreversibly to the enzyme and preventing it from further participating 
in its metabolic roles. Figure 9 demonstrates that the current study supports 
these claims; the IC50 = 1.05mM. However, at much lower concentrations 
(10nM, figure 8) 3-NPA seems to be capable of opening mitoKATP· At this low 
concentration, 3-NPA appears to have no effect on respiration. It is important 
to mention here that replicates are necessary to determine the exact dose 
range at which 3-NPA opens mitoKATP in our light scattering system. 
The influx of K+ ions through mitoKATP, observed as swelling during 
light scattering experiments, is a respiration driven process. The 
chemiosmotic gradient that is maintained by mitochondria during normal 
respiratory conditions is the same gradient that drives K+ into the matrix. If 
the concentrations of diazoxide and 3-NPA that are used to open mitoKATP 
inhibit respiration, then this swelling would not be observed (significantly 
decreased amount of swelling or even shrinkage would be observed), 
because inhibition of respiration decreases or abolishes this gradient. 
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Some investigators [79] imply that the observed cardioprotection 
results from inhibition of SDH, since diazoxide, a known SDH inhibitor, has 
been used as a model mitoKATP opener. However, my results demonstrate 
(figures 1 0a-b, 11 a-b) that other mitoKATP openers, such as PKG and 
'PERACK, do not have a significant effect on SDH function. They open 
mitoKATP at 0.25units/µL and 0.5µM, respectively [68]. PKG and 'l'ERACK do 
not activate mitoKATP directly, however, but act upstream of mitoKATP in the 
cardioprotection pathway. This fact complicates the current issue and 
experiments with compounds that activate niitoKATP directly, but have no 
effect on any part of the respiratory chain, are necessary; such drugs were 
unavailable for the current study. Interestingly, glibenclamide, a drug used to 
inhibit KATP channel opening, is known to inhibit SDH as well as mitoKATP 
opening, again demonstrating that that the mitoKATP effect is not explained by 
SDH inhibition. 
It has been suggested that ROS (reactive oxygen species) that are 
produced during respiratory inhibition are responsible for cardioprotection, 
giving a mechanism for cardioprotection via SDH inhibition. Indeed, ROS is 
central in all cardioprotection models, including the mitoKATP hypothesis. A 
small amount of ROS, regardless of its origin, protects the heart from 
ischemia [49, 130-133]. This can be clearly demonstrated by including ROS 
scavengers in an assay that measures cardioprotection or mitoKATP activity 
[131 ]. ROS scavengers also block preconditioning in Langendorff assays. In 
every case, the resulting effect is identical to that of 5-HD - abolition of 
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cardioprotection. Small amounts of ROS are known tq activate PKCE by 
oxidizing the zinc fingers the enzyme and changing its conformation [134]. 
PKCE is a critical element in all modes of cardioprotection as it is thought to 
phosphorylate and open mitoKATP [49]. Cardioprotective amounts of ROS, 
therefore, activate mitoKATP through PKCs. It has also been shown that 
inhibition of the respiratory chain produces ROS [79]. It is therefore 
conceivable that the observed cardioprotective effect includes both slight 
respiratory inhibition and activation of mitoKATP· If mild inhibition causes 
some respiration inhibition and therefore causes a production of a small 
amount of ROS then this ROS could in turn activate and open mitoKATP 
resulting in cardioprotection. In short, it is possible that diazoxide and 3-NPA, 
in small doses, inhibit respiration by an amount that does not cause 
apoptosis, but causes the production of a small amount of ROS which in turn 
activates PKCE, which finally activates mitoKATP and provides 
cardioprotection, and do not activate mitoKATP directly. 
However, it is highly unlikely that the small amount of respiratory 
inhibition we observed in the mitoKATP opening doses has any effect on ROS 
production. In order to test above hypothesis, it would be necessary to 
measure ROS production after addition of 3-NPA and to test if, perhaps, 
marginal inhibition of SDH by an SDH-specific inhibitor (such as malonate) 
causes cardioprotection in situ. At this time there is no known mechanism by 
which SDH is capable of producing ROS, which is generally produced by 
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Complex I and Complex Ill. In addition, recently, Drose et al [83] 
demonstrated that diazoxide does not generate ROS from the respiratory 
chain, making the above hypothesis even less likely. Controversy on this 
topic remains however, since Busija et al demonstrated that both 3-NPA and 
diazoxide increase mitochondrial ROS in the brain [135]. 
Ardehali et al have demonstrated that SDH is a part of a protein 
complex that is capable of transporting potassium ions, implying that SDH is 
in fact mitoKATP, or that the two proteins are closely associatedb [136]. This 
group suggests that the ability of SDH to regulate mitoKATP activity is entirely 
independent from its function in the electron transport channel [136]. A very 
recent study by Wojtovich and Brookes provides additional evidence that 
SDH and mitoKATP are closely associated [137]. They demonstrated that 
malonate, a competative inhibitor of SDH, opens mitoKATP channel even 
when the mitochondria are respiring on complex I substrates (glutamate and 
malate), at concentrations much lower than those necessary to inhibit SDH 
(137]. These data are in agreement with the dose-dependant effects of SDH 
inhibitors present in the current study. Interestingly, it has also been 
demonstrated that I PC decreases SDH activity [138]. From these data it can 
be speculated that during IPC or preconditioning by pharmacological agents, 
SDH decreases its function as a Citric Acid Cycle enzyme and electron 
transport chain enzyme and becomes involved in channeling potassium ions. 
This would also give an evolutionary reason for why SDH is imbedded in the 
inner membrane of the mitochondria. It is well established that the 
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mitochondrial shape is highly dynamic thus quick volume regulation 
mechanism seems necessary. Although this hypothesis would explain why 
SDH, which does not pump protons in the electron transport chain, is 
embedded in the membrane, it does not explain why some mitoKATP channel 
openers seem to have no effect on SDH and why some mitoKATP channel 
closers also inhibit SDH activity. In order to test this hypothesis, it would be 
necessary to confirm the speculation that SDH is capable of shuttling K+ and 
measure SDH enzymatic activity at the same time as K+ transport (or 
mitoKATP activity). 
It is well known that many of the agents used in studying cardiac 
preconditioning have other effects on the heart, seemingly unrelated to their 
effects on the mitoKATP channel. It would be ideal to study the effects of these 
agents in situ, without disruption of cardiac myocytes. It is likely that 
mitochondrial isolation greatly disrupts the natural shape of each 
mitochondrion. At this point, unfortunately, there are no available techniques 
to do this. 
The dose-response curves for both 3-NPA and diazoxide yielded a Hill 
slope that is greater than 1 (figures 7, 9). It is important to point out that the 
system we tested is not an isolated one. Mitochondria purified in a crude, 
differential centrifugation manner was utilized in all our assays. Therefore, it 
is not feasible to create a perfect dose response curve with a Hill slope of 1. 
For such an experiment, in order to describe the exact binding manner of 
drug to SDH, it would be necessary to work with isolated SDH. In both cases 
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the Hill slope indicates some degree of cooperative binding. In fact, it is 
impossible to determine, in the present study, whether these drugs are acting 
only on SDH, and not having other unknown effects on the electron transport 
chain. Conceivably, it is possible that both diazoxide and 3-NPA affect other 
components of the electron transport chain causing an increase in ROS from 
complexes I or Ill. The current design of the study is, however, more relevant 
to the physiological conditions that we were attempting to assess. 
Additionally, the purpose of this study was not to obtain exact drug 
concentrations, but to assess whether or not succinate-supported respiration 
is significantly inhibited in doses that are used for mitoKATP opening. 
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5. Conclusions 
Cardiac disease is the most common cause of death in the United 
States and in the world, therefore, understanding the details of its mechanism 
is of great importance to public health. lschemic preconditioning, in 
particular, is an interesting phenomenon with a possibility of wide implications 
in the clinical field. Understanding how it works and how it can be 
manipulated is crucial. 
The goal of the research presented in this thesis was to clarify if 
preconditioning by potassium channel openers is through the inhibition of 
succinate dehydrogenase, complex II of the electron chain, as has been 
claimed by some investigators, or if this kind of preconditioning is mediated 
by mitochondrial ATP-sensitive potassium channel. The results of this study 
indicate that the doses of potassium channel openers used to open mitoKArP 
in light scattering assays are insufficient to cause any significant respiratory 
inhibition. In addition, PKG and 'I'ERACK, which are known to open mitoKArP 
do not inhibit respiration at any dose tested. 
Therefore, it appears that preconditioning by diazoxide, 3-NPA, PKG, 
and 'I'ERACK is mediated by mitoKArP as previously suggested and not 
through the inhibition of succinate dehydrogenase. Many possible directions 




[1] W. Rosamond, K. Flegal, G. Friday, K. Furie, A. Go, K. Greenlund, N. 
Haase, M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lloyd-Jones, M. 
McDermott, J. Meigs, C. Moy, G. Nichol, C.J. O'Donnell, V. Roger, J. 
Rumsfeld, P. Sorlie, J. Steinberger, T. Thom, S. Wasserthiel-Smoller 
and Y. Hong, Heart Disease and Stroke Statistics--2007 Update: A 
Report From the American Heart Association Statistics Committee and 
Stroke Statistics Subcommittee, Circulation 115 (2007) e69-171. 
[2] J.M. Downey, A.M. Davis and M.V. Cohen, Signaling pathway in 
ischemic preconditioning, Heart Fail Rev 12 (2007) 181-8. 
[3] G. Solaini and D.A. Harris, Biochemical dysfunction in heart 
mitochondria exposed to ischaemia and reperfusion., Biochem J 390 
(2005) 377-94. 
[4] G.P. Dobson and U.U. Himmelreich, Heart design: free ADP scales 
with absolute mitochondrial and myofibrillar volumes from mouse to 
human, Biochim Biophys Acta 1553 (2002) 261-7. 
[5] A.P. Halestrap, S.J. Clarke and I. Khaliulin, The role of mitochondria in 
protection of the heart by preconditioning, Biochim Biophys Acta 1767 
(2007) 1007-31. 
[6] K. Vuorinen, K. Ylitalo, K. Peuhkurinen, P. Raatikainen, A. Ala-Rami 
and I.E. Hassinen, Mechanisms of lschemic Preconditioning in Rat 
Myocardium : Roles of Adenosine, Cellular Energy State, and 
Mitochondrial F1 Fo-ATPase, Circulation 91 (1995) 2810-8. 
[7] G. Ambrosio, J.L. Zweier, C. Duilio, P. Kuppusamy, G. Santoro, P.P. 
Elia, I. Tritto, P. Cirillo, M. Condorelli, M. Chiariello and et al., Evidence 
that mitochondrial respiration is a source of potentially toxic oxygen 
· free radicals in intact rabbit hearts subjected to ischemia and reflow, J 
Biol Chem. 268 (1993) 18532-41. 
[8] M. Lazdunski, C. Frelin and P.U. Vigne, The sodium/hydrogen 
exchange system in cardiac cells: Its biochemical and pharmacological 
properties and its role in regulating internal concentrations of sodium 
and internal pH, J Mol Cell Cardiol. 17 (1985) 1029-42. 
[9] C. Frelin, P. Vigne and M. Lazdunski, The role of the Na+/H+ 
54 
exchange system in cardiac cells in relation to the control of the 
internal Na+ concentration. A molecular basis for the antagonistic 
effect of ouabain and amiloride on the heart, J Biol Chem 259 (1984) 
8880-5. 
[1 O] M. Tani and J. Neely, Role of intracellular Na+ in Ca2+ overload and 
depressed recovery of ventricular function of reperfused ischemic rat 
hearts. Possible involvement of H+-Na+ and Na+-Ca2+ exchange, Circ 
Res 65 (1989) 1045-56. 
[11] R. Vaughan-Jones and M. Wu, Extracellular H+ inactivation of Na(+)-
H+ exchange in the sheep cardiac Purkinje fibre, J Physiol (Lond) 428 
(1990) 441-66. 
[12] H.H. Klein, S. Pich, R.M. Bohle, S. Lindert-Heimberg and K. 
Nebendahl, Na+/H+ Exchange Inhibitor Cariporide Attenuates Cell 
Injury Predominantly During lschemia and Not at Onset of Reperfusion 
in Porcine Hearts With Low Residual Blood Flow, Circulation 102 
(2000) 1977-82. 
[13] L.B. Becker, New concepts in reactive oxygen species and 
cardiovascular reperfusion physiology, Cardiovasc Res 61 (2004) 461-
70. 
[14] LG. Kevin, P. Katz, A.K. Camara, E. Novalija, M.L. Riess and D.F. 
Stowe, Anesthetic preconditioning: effects on latency to ischemic injury 
in isolated hearts, Anesthesiology 99 (2003) 385-91. 
[15] P. Eaton, H.L. Byers, N. Leeds, M.A. Ward and M.J. Shattock, 
Detection, quantitation, purification, and identification of cardiac 
proteins S-thiolated during ischemia and reperfusion, J Biol Chem 277 
(2002) 9806-11. 
[16] LC. Hool, Reactive oxygen species in cardiac signalling: from 
mitochondria to plasma membrane ion channels, Clin Exp Pharmacol 
Physiol 33 (2006) 146-51. 
[17] H.M. Honda, P. Karge and J.N. Weiss, Mitochondria and 
ischemia/reperfusion injury, Ann NY Acad Sci 1047 (2005) 248-58. 
[18] R.A. Gottlieb, Mitochondria and apoptosis, Biol Signals Recept 1 O 
(2001) 147-61. 
[19] R.A. Gottlieb, Mitochondrial signaling in apoptosis: mitochondrial 
daggers to the breaking heart, Basic Res Cardiol 98 (2003) 242-9. 
55 
[20] E. Doran and A.P. Halestrap, Cytochrome c release from isolated rat 
liver mitochondria can occur independently of outer-membrane 
rupture: possible role of contact sites, Biochem J 348 (2000) 343-50. 
[21] S.E. Logue, A.B. Gustafsson, A. Samali and R.A. Gottlieb, 
lschemia/reperfusion injury at the intersection with cell death, J Mol 
Cell Cardiol 38 (2005) 21-33. 
[22] C.E. Murry, R.B. Jennings and K.A. Reimer, Preconditioning with 
ischemia: a delay of lethal cell injury in ischemic myocardium, 
Circulation 7 4 ( 1986) 1124-36. 
[23] N. Kaeffer, V. Richard, A. Francois, F. Lallemand, J.P. Henry and C. 
Thuillez, Preconditioning prevents chronic reperfusion-induced 
coronary endothelial dysfunction in rats, Am J Physiol Heart Circ 
Physiol 271 (1996) H842-9. 
[24] D.M. Yellon and J.M. Downey, Preconditioning the Myocardium: From 
Cellular Physiology to Clinical Cardiology, Physiol Rev 83 (2003) 1113-
51. 
[25] R.C. Kukreja, F. Salloum, A. Das, R. Ockaili, C. Yin, Y.A. Bremer, 
P.W. Fisher, M. Wittkamp, J. Hawkins, E. Chou, A.K. Kukreja, X. 
Wang, V.R. Marwaha and L. Xi, Pharmacological preconditioning with 
sildenafil: Basic mechanisms and clinical implications, Vascul 
Pharmacol 42 (2005) 219-32. 
[26] D.R. Meldrum, J.C.J. Cleveland, M.B. Mitchell, R.T. Rowland, A. 
Banerjee and A.H. Harken, Constructive priming of myocardium 
against ischemia-reperfusion injury, Shock 6 (1996) 238-42. 
[27] G.J. Grover, J.R. McCullough, D.E. Henry, M.L. Conder and P.G. 
Sleph, Anti-ischemic effects of the potassium channel activators 
pinacidil and cromakalim and the reversal of these effects with the 
potassium channel blocker glyburide, J Pharmacol Exp Ther 251 
(1989) 98-104. 
[28] R.J. Gumina, E. Buerger, C. Eickmeier, J. Moore, J. Daemmgen and 
G.J. Gross, Inhibition of the Na(+)/H(+) exchanger confers greater 
cardioprotection against 90 minutes of myocardial ischemia than 
ischemic preconditioning in dogs, Circulation 100 (1999) 2519-26; 
discussion 2469-72. 
[29] R.M. Mentzer, Jr., R.D. Lasley, A. Jessel and M. Karmazyn, 
Intracellular sodium hydrogen exchange inhibition and clinical 
56 
myocardial protection, Ann Thorac Surg 75 (2003) S700-8. 
[30] Z.Q. Zhao, J.S. Corvera, M.E. Halkos, F. Kerendi, N.P. Wang, R.A. 
Guyton and J. Vinten-Johansen, Inhibition of myocardial injury by 
ischemic post-conditioning during reperfusion: comparison with 
ischemic preconditioning, Am J Physiol 3 (2003) 3. 
[31] J.P. Arena and R.S. Kass, Block of heart potassium channels by 
clofilium and its tertiary analogs: relationship between drug structure 
and type of channel blocked, Mal Pharmacol 34 (1988) 60-6. 
[32] W. Osterrieder, Modification of K+ conductance of heart cell 
membrane by BRL 34915, Naunyn Schmiedebergs Arch Pharmacol 
337 (1988) 93-7. 
[33] H. Schmid-Antomarchi, J. De Weille, M. Fosset and M. Lazdunski, The 
receptor for antidiabetic sulfonylureas controls the activity of the ATP-
modulated K + channel in insulin-secreting cells, J Biol Chem 262 
(1987) 15840-4. 
[34] G.J. Gross, D.C. Warltier and H.F. Hardman, Comparative effects of 
nicorandil, a nicotinamide nitrate derivative, and nifedipine on 
myocardial reperfusion injury in dogs, J Cardiovasc Pharmacol 10 
(1987) 535-42. 
[35] G.J. Grover, S. Dzwonczyk, C.S. Parham and P.G. Sleph, The 
protective effects of cromakalim and pinacidil on reperfusion function 
and infarct size in isolated perfused rat hearts and anesthetized dogs, 
Cardiovasc Drugs Ther 4 (1990) 465-74. 
[36] G.J. Grover, J. Newburger, P.G. Sleph, S. Dzwonczyk, S.C. Taylor, 
S.Z. Ahmed and K.S. Atwal, Cardioprotective effects of the potassium 
channel opener cromakalim: stereoselectivity and effects on 
myocardial adenine nucleotides, J Pharmacol Exp Ther 257 (1991) 
156-62. 
[37] W.C. Cole, C.D. McPherson and D. Sontag, ATP-regulated K+ 
channels protect the myocardium against ischemia/reperfusion 
damage, Circ Res 69 (1991) 571-81. 
[38] H. Ohta, Y. Jinno, K. Harada, N. Ogawa, H. Fukushima and K. 
Nishikori, Cardioprotective effects of KRN2391 and nicorandil on 
ischemic dysfunction in perfused rat heart, Eur J Pharmacol 204 
(1991) 171-7. 
57 
[39] M. Galinanes, M.J. Shattock and D.J. Hearse, Effects of potassium 
channel modulation during global ischaemia in isolated rat heart with 
and without cardioplegia, Cardiovasc Res 26 (1992) 1063-8. 
[40] H.L. Tan, P. Mazon, H.J. Verberne, M.E. Sleeswijk, R. Coronel, T. 
Opthof and M.J. Janse, lschaemic preconditioning delays ischaemia 
induced cellular electrical uncoupling in rabbit myocardium by 
activation of ATP sensitive potassium channels, Cardiovasc Res 27 
(1993) 644-51. 
[41] G.J. Grover, Protective effects of ATP sensitive potassium channel 
openers in models of myocardial ischaemia, Cardiovasc Res 28 (1994) 
778-82. 
[42] G.J. Grover, A.J. D'Alonzo, C.S. Parham and R.B. Darbenzio, 
Cardioprotection with the KA TP opener cromakalim is not correlated 
with ischemic myocardial action potential duration, J Cardiovasc 
Pharmacol 26 (1995) 145-52. 
[43] G.J. Gross, ATP-sensitive potassium channels and myocardial 
preconditioning, Basic Res Cardiel 90 (1995) 85-8. 
[44] J.F. Faivre and I. Findlay, Effects of tolbutamide, glibenclamide and 
diazoxide upon action potentials recorded from rat ventricular muscle, 
Biochim Biophys Acta 984 (1989) 1-5. 
[45] I. Inoue, H. Nagase, K. Kishi and T. Higuti, ATP-sensitive K+ channel 
in the mitochondrial inner membrane, Nature 352 ( 1991) 244-7. 
[46] P. Paucek, G. Mironova, F. Mahdi, A.O. Beavis, G. Woldegiorgis and 
K.D. Garlid, Reconstitution and partial purification of the glibenclamide-
sensitive, ATP-dependent K+ channel from rat liver and beef heart 
mitochondria, J Biol Chem 267 (1992) 26062-9. 
[47] K.D. Garlid, P. Paucek, V. Yarov-Yarovoy, X. Sun and P.A. Schindler, 
The mitochondrial KArP channel as a receptor for potassium channel 
openers, J Biol Chem 271 (1996) 8796-9. 
[48] K.D. Garlid, P. Paucek, V. Yarov-Yarovoy, H.N. Murray, R.B. 
Darbenzio, A.J. D'Alonzo, N.J. Lodge, M.A. Smith and G.J. Grover, 
Cardioprotective effect of diazoxide and its interaction with 
mitochondrial ATP-sensitive K+ channels. Possible mechanism of 
cardioprotection, Circ Res 81 (1997) 1072-82. 
[49] A.O. Costa, R. Jakob, C.L. Costa, K. Andrukhiv, I.C. West and K.D. 
58 
Garlid, The mechanism by which the mitochondrial ATP-sensitive K+ 
channel opening and H2O2 inhibit the mitochondrial permeability 
transition, J Biol Chem 281 (2006) 20801-8. 
[50] J.D. Mccully and S. Levitsky, The mitochondrial K(ATP} channel and 
cardioprotection, Ann Thorac Surg 75 (2003) S667-73. 
[51] B. O'Rourke, Evidence for mitochondrial K+ channels and their role in 
cardioprotection, Circ Res 94 (2004) 420-32. 
[52] 0. Oldenburg, M.V. Cohen, D.M. Yellon and J.M. Downey, 
Mitochondrial KATP channels: role in cardioprotection, Cardiovasc Res 
55 (2002) 429-37. 
[53] G.J. Gross and R.M. Fryer, Sarcolemmal versus mitochondrial ATP-
sensitive K+ channels and myocardial preconditioning, Circ Res 84 
(1999) 973-9. 
[54] Y. Liu, T. Sato, B. O'Rourke and E. Marban, Mitochondrial ATP-
dependent potassium channels: novel effectors of cardioprotection?, 
Circulation 97 (1998) 2463-9. 
[55] T. Sato, B. O'Rourke and E. Marban, Modulation of mitochondrial 
ATP-dependent K+ channels by protein kinase C, Circ Res 83 (1998) 
110-4. 
[56] K.D. Garlid, P. Dos Santos, 2.-J. Xie, A.D.T. Costa and P. Paucek, 
Mitochondrial potassium transport: the role of the mitochondrial ATP-
sensitive K+ channel in cardiac function and cardioprotection, Biochim 
Biophys Acta 1606 (2003) 1-21. 
[57] J. Liu, J. Tian, M. Haas, J.I. Shapiro, A. Askari and Z. Xie, Ouabain 
interaction with cardiac Na+/K+-ATPase initiates signal cascades 
independent of changes in intracellular Na+ and Ca2+ concentrations, 
J Biol Chem 275 (2000) 27838-44. 
[58] J. Tian, J. Liu, K.D. Garlid, J.I. Shapiro and Z. Xie, Involvement of 
Mitogen-activated Protein Kinases and Reactive Oxygen Species in 
the lnotropic Action of Ouabain on Cardiac Myocytes. A Potential Role 
for Mitochondrial KATP Channels, Mol Cell Biochem 242 (2003) 181-
187. 
[59] H. Hauner, Insulin resistance and the metabolic syndrome-a challenge 
of the new millennium, Eur J Clin Nutr 56 (2002) S25-9. 
59 
[60] D.J. Hausenloy, A. Tsang, M.M. Mocanu and D.M. Yellon, lschemic 
preconditioning protects by activating prosurvival kinases at 
reperfusion, Am J Physiol 288 (2005) H971-6. 
[61] D.J. Hausenloy, A. Tsang and D.M. Yellon, The reperfusion injury 
salvage kinase pathway: a common target for both ischemic 
preconditioning and postconditioning, Trends Cardiovasc Med 15 
(2005) 69-75. 
[62] P. Karge, H.M. Honda and J.N. Weiss, Regulation of the mitochondrial 
permeability transition by matrix Ca(2+) and voltage during 
anoxia/reoxygenation, Am J Physiol 280 (2001) C517-26. 
[63] P. Karge, H.M. Honda and J.N. Weiss, Protection of cardiac 
mitochondria by diazoxide and protein kinase C: implications for 
ischemic preconditioning, Proc Natl Acad Sci US A 99 (2002) 3312-7. 
[64] C.P. Baines, C.X. Song, Y.T. Zheng, G.W. Wang, J. Zhang, O.L. 
Wang, Y. Guo, R. Balli, E.M. Cardwell and P. Ping, Protein kinase 
Cepsilon interacts with and inhibits the permeability transition pore in 
cardiac mitochondria, Circ Res 92 (2003) 873-80. 
[65] K. Inagaki, R. Begley, F. lkeno and D. Mochly-Rosen, Cardioprotection 
by epsilon-protein kinase C activation from ischemia: continuous 
delivery and antiarrhythmic effect of an epsilon-protein kinase C-
activating peptide, Circulation 111 (2005) 44-50. 
[66] A.T. Saurin, D.J. Pennington, N.J. Raat, D.S. Latchman, M.J. Owen 
and M.S. Marber, Targeted disruption of the protein kinase C epsilon 
gene abolishes the infarct size reduction that follows ischaemic 
preconditioning of isolated buffer-perfused mouse hearts, Cardiovasc 
Res 55 (2002) 672-80. 
[67] J.S. Kim, S. Ohshima, P. Pediaditakis and J.J. Lemasters, Nitric oxide 
protects rat hepatocytes against reperfusion injury mediated by the 
mitochondrial permeability transition, Hepatology 39 (2004) 1533-43. 
[68] A.D. Costa, K.D. Garlid, I.C. West, T.M. Lincoln, J.M. Downey, M.V. 
Cohen and S.D. Critz, Protein Kinase G Transmits the 
Cardioprotective Signal From Cytosol to Mitochondria, Circ Res 97 
(2005) 329-36. 
[69] A. Andrukhiv, A.D. Costa, I.C. West and K.D. Garlid, Opening 
mitoKATP increases superoxide generation from Complex I of the 
electron transport chain, Am J Physiol Heart Circ Physiol (2006) 
60 
H2067-207 4. 
(70] K.D. Garlid. in (Lemasters, J.J., Hackenbrock, C.R., Thurman, R.G. 
and Westerhoff, H.V., eds.) Integration of Mitochondrial Function, 
Plenum Publishing Corp., New York 1988, pp. 257-276. 
(71] A.J. Kowaltowski, S. Seetharaman, P. Paucek and K.D. Garlid, 
Bioenergetic consequences of opening the ATP-sensitive K+ channel 
of heart mitochondria, Am J Physiol 280 (2001) H649-57. 
(72] K.D .. Garlid, A.D. Beavis and S.K. Ratkje, On the nature of ion leaks in 
energy-transducing membranes, Biochim Biophys Acta 976 (1989) 
109-20. 
(73] Q. Huang, S. Bu, Y. Yu, Z. Guo, G. Ghatnekar, M. Bu, L. Yang, 8. Lu, 
Z. Feng, S. Liu and F. Wang, Diazoxide prevents diabetes through 
inhibiting pancreatic beta-cells from apoptosis via Bcl-2/Bax rate and 
p38-beta mitogen-activated protein kinase, Endocrinology 148 (2007) 
81-91. 
[74] Y. Li, V. Sharov, N. Jiang, C. Zaloga, H. Sabbah and M. Chopp, 
Ultrastructural and light microscopic evidence of apoptosis after middle 
cerebral artery occlusion in the rat, Am J Pathol 146 (1995) 1045-
1051. 
(75] R. Bajgar, S. Seetharaman, A.J. Kowaltowski, K.D. Garlid and P. 
Paucek, Identification and properties of a novel intracellular 
(mitochondrial) ATP-sensitive potassium channel in brain, J Biol Chem 
276 (2001) 33369-74. 
[76] F. Domoki, J.V. Perciaccante, R. Veltkamp, F. Bari and D.W. Busija, 
Mitochondrial potassium channel opener diazoxide preserves 
neuronal-vascular function after cerebral ischemia in newborn pigs, 
Stroke 30 (1999) 2713-8; discussion 2718-9. 
[77] J.G. Shake, E.A. Peck, E. Marban, V.L. Gott, M.V. Johnston, J.C. 
Troncoso, J.M. Redmond and W.A. Baumgartner, Pharmacologically 
induced preconditioning with diazoxide: a novel approach to brain 
protection, Ann Thorac Surg 72 (2001) 1849-54. 
(78] Y. Tashima, M. Akao, R.A. Li, T.H. Chong, W.A. Baumgartner, M.V. 
Johnston and E. Marban, Mitochondrial ATP-sensitive potassium 
channel activation protects cerebellar granule neurons from apoptosis 
induced by oxidative stress, Stroke 34 (2003) 1796-802. 
61 
[79] J. Minners, L. Lacerda, D. Yellon, L. Opie, C. McLeod and M. Sack, 
Diazoxide-induced respiratory inhibition -- a putative mitochondrial 
KA TP channel independent mechanism of pharmacological 
preconditioning, Mol Cell Biochem 294 (2007) 11-8. 
[80] C. Ozcan, M. Bienengraeber, P.P. Dzeja and A. Terzic, Potassium 
channel openers protect cardiac mitochondria by attenuating oxidant 
stress at reoxygenation, Am J Physiol Heart Circ Physiol 282 (2002) 
H531-9. 
[81] P.J. Hanley, M. Mickel, M. Loffler, U. Brandt and J. Daut, KATP channel-
independent targets of diazoxide and 5-hydroxydecanoate in the heart, 
J Physiol 542 (2002) 735-41. 
[82] K.H. Lim, S.A. Javadov, M. Das, S.J. Clarke, M.S. Suleiman and A.P. 
Halestrap, The effects of ischaemic preconditioning, diazoxide and 5-
hydroxydecanoate on rat heart mitochondrial volume and respiration, J 
Physiol 545 (2002) 961-74. 
[83] S. Drose, U. Brandt and P.J. Hanley, K+-independent Actions of 
Diazoxide Question the Role of Inner Membrane KA TP Channels in 
Mitochondrial Cytoprotective Signaling, J Biol Chem. 281 (2006) 
23733-9. 
[84] P .J. Hanley and J. Daut, K(ATP) channels and preconditioning: a re-
examination of the role of mitochondrial K(ATP) channels and an 
overview of alternative mechanisms, J Mol Cell Cardiol 39 (2005) 17-
50. 
[85] G. Schafer, C. Wegener, R. Portenhauser and D. Bojanovski, 
Diazoxide, an inhibitor of succinate oxidation, Biochem Pharmacol 18 
(1969) 2678-81. 
[86] K. Moritani, T. Miyazaki, S. Miyoshi, M. Asanagi, LS. Zhao, H. 
Mitamura and S. Ogawa, Blockade of ATP-sensitive potassium 
channels by 5-hydroxydecanoate suppresses monophasic action 
potential shortening during regional myocardial ischemia, Cardiovasc 
Drugs Ther 8 (1994) 749-56. 
[87] J. Munch-Ellingsen, J.E. Lokebo, E. Bugge, A.K. Jonassen, T. 
Ravingerova and K. Ytrehus, 5-HD abolishes ischemic preconditioning 
independently of monophasic action potential duration in the heart, 
Basic Res Cardiol 95 (2000) 228-34. 
[88] M. Krenz, 0. Oldenburg, H. Wimpee, M.V. Cohen, K.D. Garlid, S.D. 
62 
Critz, J.M. Downey and J.N. Benoit, Opening of ATP-sensitive 
potassium channels causes generation of free radicals in vascular 
smooth muscle cells, Basic Res Cardiel 97 (2002) 365-73. 
[89] M.P. Morris, C. Pagan and H.E. Warmke, Hiptagenic Acid, a Toxic 
Component of lndigofera endecaphylla, Science 119 (1954) 322-3. 
[90] T.A. Alston, L. Mela and H.J. Bright, 3-Nitropropionate, the Toxic 
Substance of lndigofera, is a Suicide lnactivator of Succinate 
Dehydrogenase, Proc Natl Acad Sci US A 74 (1977) 3767-71. 
[91] P.A. Nony, A.C. Scallet, R.L. Rountree, X. Ye and Z. Binienda, 3-
Nitropropionic acid (3-NPA) produces hypothermia and inhibits 
histochemical labeling of succinate dehydrogenase (SDH) in rat brain, 
Metab Brain Dis 14 (1999) 83-94. 
[92] L.F. James, W.J. Hartley, M.C. Williams and K.R. Van Kampen, Field 
and experimental studies in cattle and sheep poisoned by nitre-bearing 
Astragalus or their toxins, Am J Vet Res 41 (1980) 377-82. 
[93] A.C. Ludolph, M. Seelig, A.G. Ludolph, M.I. Sabri and P .S. Spencer, 
ATP deficits and neuronal degeneration induced by 3-nitropropionic 
acid, Ann NY Acad Sci 648 (1992) 300-2. 
[94] C.J. Coles, D.E. Edmondson and T.P. Singer, Inactivation of succinate 
dehydrogenase by 3-nitropropionate, J Biol Chem 254 (1979) 5161-7. 
[95] M.W. Riepe and A.C. Ludolph, Chemical preconditioning: a 
cytoprotective strategy, Mol Cell Biochem 174 (1997) 249-54. 
[96] F. Wiegand, W. Liao, C. Busch, S. Castell, F. Knapp, U. Lindauer, D. 
Megow, A. Meisel, A. Redetzky, K. Ruscher, G. Trendelenburg, I. 
Victorov, M. Riepe, H.C. Diener and U. Dirnagl, Respiratory chain 
inhibition induces tolerance to focal cerebral ischemia, J Cereb Blood 
Flow Metab 19 (1999) 1229-37. 
[97] A.M. Brambrink, A. Schneider, H. Noga, A. Astheimer, B. Gatz, I. 
Korner, A. Heimann, M. Welschof and 0. Kempski, Tolerance-
Inducing dose of 3-nitropropionic acid modulates bcl-2 and bax 
balance in the rat brain: a potential mechanism of chemical 
preconditioning, J Cereb Blood Flow Metab 20 (2000) 1425-36. 
[98] M. Erecinska and D. Nelson, Effects of 3-Nitropropionic Acid on 
Synaptosomal Energy and Transmitter Metabolism: Relevance to 
Neurodegenerative Brain Diseases, J Neurochem 63 ( 1994) 1033-41. 
63 
[99] Z. Pang and J.W. Geddes, Mechanisms of cell death induced by the 
mitochondrial toxin 3-nitropropionic acid: acute excitotoxic necrosis 
and delayed apoptosis, J Neurosci 17 (1997) 3064-73. 
[100] H. Sato, T. Miki, R.P. Vallabhapurapu, P. Wang, G.S. Liu, M.V. Cohen 
and J.M. Downey, The mechanism of protection from 5 (N-ethyl-N-
isopropyl)amiloride differs from that of ischemic preconditioning in 
rabbit heart, Basic Research In Cardiology 92 (1997) 339-50. 
[101] M. Riepe, N. Hori, A.C. Ludolph, D.O. Carpenter, P.S. Spencer and 
C.N. Allen, Inhibition of energy metabolism by 3-nitropropionic acid 
activates ATP-sensitive potassium channels, Brain Res 586 (1992) 61-
6. 
[102] T. Horiguchi, B. Kis, N. Rajapakse, K. Shimizu and D.W. Busija, 
Opening of mitochondrial ATP-sensitive potassium channels is a 
trigger of 3-nitropropionic acid-induced tolerance to transient focal 
cerebral ischemia in rats, Stroke 34 (2003) 1015-20. 
[103] Z. Hu, Y. Yang, K. Zhang and Z. Sun, Chemical preconditioning by 3-
nitropropionic acid reduces ischemia-reperfusion injury in rat heart, J 
Huazhong Univ Sci Technolog Med Sci 25 (2005) 439-41. 
[104] R.A. Ockaili, P. Bhargava and R.C. Kukreja, Chemical preconditioning 
with 3-nitropropionic acid in hearts: role of mitochondrial KATP channel, 
Am J Physiol 280 (2001) H2406-11. 
[105] U. Panten, J. Burgfeld, F. Goerke, M. Rennicke, M. Schwanstecher, A. 
Wallasch, B.J. Zunkler and S. Lenzen, Control of insulin secretion by 
sulfonylureas, meglitinide and diazoxide in relation to their binding to 
the sulfonylurea receptor in pancreatic islets, Biochem Pharmacol 38 
(1989) 1217-29. 
[106] J. Varon and P.E. Marik, The Diagnosis and Management of 
Hypertensive Crises, Chest 118 (2000) 214-27. 
[107] E.A. Belyaeva, A. Szewczyk, B. Mikolajek, M.J. Nalecz and L. 
Wojtczak, Demonstration of glibenclamide-sensitive K + fluxes in rat 
liver mitochondria, Biochem Mol Biol Int 31 (1993) 493-500. 
[108] A. Szewczyk, G. Wojcik and M.J. Nalecz, Potassium channel opener, 
RP 66471, induces membrane depolarization of rat liver mitochondria, 
Biochem Biophys Res Commun 207 (1995) 126-32. 
[109] N.S. Cook and U. Quast, Potassium channel pharmacology., In: 
64 
Potassium channels (Cook, N.S., ed.) Ellis Harwood Ltd., pp 181-231. 
(1990). 
[110] C.P. Baines, J. Zhang, G.-W. Wang, Y.-T. Zheng, J.X. Xiu, E.M. 
Cardwell, R. Balli and P. Ping, Mitochondrial PKC• and MAPK form 
signaling modules in the murine heart: enhanced mitochondrial PKC• -
MAPK interactions and differential MAPK activation in PKC• -induced 
cardioprotection, Circ Res 90 (2002) 390-7. 
[111] L. Chen, H. Hahn, G. Wu, C.H. Chen, T. Liron, D. Schechtman, G. 
Cavallaro, L. Banci, Y. Guo, R. Balli, G.W. Dorn, 2nd and D. Mochly-
Rosen, Opposing cardioprotective actions and parallel hypertrophic 
effects of delta PKC and epsilon PKC, Proc Natl Acad Sci U S A 98 
(2001) 11114-9. 
[112] D. Guo, T. Nguyen, M. Ogbi, H. Tawfik, G. Ma, Q. Yu, R.W. Caldwell 
and J.A. Johnson, Protein kinase C-epsilon coimmunoprecipitates with 
cytochrome oxidase subunit IV and is associated with improved 
cytochrome-c oxidase activity and cardioprotection, Am J Physiol 
Heart Circ Physiol 293 (2007) H2219-30. 
[113] K. Inagaki, H.S. Hahn, G.W. Dorn, 2nd and D. Mochly-Rosen, Additive 
protection of the ischemic heart ex vivo by combined treatment with 
delta-protein kinase C inhibitor and epsilon-protein kinase C activator, 
Circulation 108 (2003) 869-75. 
[114] P. Ping, J. Zhang, Y. Qiu, X.L. Tang, S. Manchikalapudi, X. Cao and 
R. Balli, lschemic preconditioning induces selective translocation of 
protein kinase C isoforms epsilon and eta in the heart of conscious 
rabbits without subcellular redistribution of total protein kinase C 
activity, Circ Res 81 (1997) 404-14. 
[115] G.W. Dorn, M.C. Souroujon, T. Liron, C.H. Chen, M.O. Gray, H.Z. 
Zhou, M. Csukai, G. Wu, J.N. Lorenz and D. Mochly Rosen, Sustained 
in vivo cardiac protection by a rationally designed peptide that causes 
epsilon protein kinase C translocation, Proc Natl Acad Sci U S A 96 
(1999) 12798-803. 
[116] A. Nakano, M.V. Cohen and J.M. Downey, lschemic preconditioning. 
From basic mechanisms to clinical applications, Pharmacol Ther 86 
(2000) 263-75. 
[117] A. Das, A. Smolenski, S.M. Lohmann and R.C. Kukreja, Cyclic GMP-
dependent Protein Kinase l{alpha} Attenuates Necrosis and Apoptosis 
Following lschemia/Reoxygenation in Adult Cardiomyocyte, J. Biol. 
65 
Chem. 281 (2006) 38644-52. 
[118] T.M. Lincoln, N. Dey and H. Sellak, Signal Transduction in Smooth 
Muscle: Invited Review: cGMP-dependent protein kinase signaling 
mechanisms in smooth muscle: from the regulation of tone to gene 
expression, J Appl Physiol 91 (2001) 1421-30. 
[119] F. Hofmann, A. Ammendola and J. Schlossmann, Rising behind NO: 
cGMP-dependent protein kinases, J Cell Sci 113 (2000) 1671-6. 
[120] J. Han, N. Kim, E. Kim, W.-K. Ho and Y.E. Earm, Modulation of ATP-
sensitive Potassium Channels by cGMP-dependent Protein Kinase in 
Rabbit Ventricular Myocytes, J Biol Chem 276 (2001) 22140-7. 
[121] 0. Oldenburg, Q. Qin, T. Krieg, X.-M. Yang, S. Philipp, S.D. Critz, M.V. 
Cohen and J.M. Downey, Bradykinin induces mitochondrial ROS 
generation via NO, cGMP, PKG, and mitoKArP channel opening and 
leads to cardioprotection, Am J Physiol 286 (2004) H468-76. 
[122] A.G. Gornall, C.J. Bardawill and M.M. David, Determination of serum 
proteins by means of the biuret reaction, J Biol Chem 177 (1949) 751-
66. 
[123] A.O. Beavis, R.D. Brannan and K.D. Garlid, Swelling and contraction 
of the mitochondrial matrix. I. A structural interpretation of the 
relationship between light scattering and matrix volume, J Biol Chem 
260 ( 1985) 13424-33. 
[124] H. Tedeschi and D.L. Harris, The osmotic behavior and permeability to 
non-electrolytes of mitochondria, Arch Biochem Biophys 58 (1955) 52-
67. 
[125] G.J. Gross and J.A. Auchampach, Role of ATP dependent potassium 
channels in myocardial ischaemia, Cardiovasc Res 26 (1992) 1011-6. 
[126] M.E. Speechly-Dick, G.J. Grover and D.M. Yellon, Does ischemic 
preconditioning in the human involve protein kinase C and the ATP-
dependent K+ channel? Studies of contractile function after simulated 
ischemia in an atrial in vitro model, Circ Res 77 (1995) 1030-5. 
[127] R.A. Kloner, R. Balli, E. Marban, L. Reinlib and E. Braunwald, Medical 
and cellular implications of stunning, hibernation, and preconditioning: 
an NHLBI workshop, Circulation 97 (1998) 1848-67. 
[128] J.P.t. Clement, K. Kunjilwar, G. Gonzalez, M. Schwanstecher, U. 
66 
Panten, L. Aguilar-Bryan and J. Bryan, Association and stoichiometry 
of K(ATP) channel subunits, Neuron 18 ( 1997) 827-38. 
[129] M.J. MacDonald, The use of calcium uptake by small amounts of 
mitochondria from pancreatic islets to study mitochondrial respiration: 
the effects of diazoxide and sodium, Biochem Int 8 (1984) 771-8. 
[130] D.K. Das, N. Maulik, M. Sato and P.S. Ray, Reactive oxygen species 
function as second messenger during ischemic preconditioning of 
heart, Mol Cell Biochem 196 (1999) 59-67. 
[131] R.A. Forbes, C. Steenbergen and E. Murphy, Diazoxide-lnduced 
Cardioprotection Requires Signaling Through a Redox-Sensitive 
Mechanism, Circ Res 88 (2001) 802-9. 
[132] I. Tritto, D. D'Andrea, N. Eramo, A. Scognamiglio, C. De Simone, A. 
Violante, A. Esposito, M. Chiariello and G. Ambrosio, Oxygen radicals 
can induce preconditioning in rabbit hearts, Circ Res 80 (1997) 7 43-8. 
[133] 0. Oldenburg, S.D. Critz, M.V. Cohen and J.M. Downey, 
Acetylcholine-induced production of reactive oxygen species in adult 
rabbit ventricular myocytes is dependent on phosphatidylinositol 3- and 
Src-kinase activation and mitochondrial KATP channel opening, J Mol 
Cell Cardiol 35 (2003) 653-60. 
[134] I. Korichneva, B. Hoyos, R. Chua, E. Levi and U. Hammerling, Zinc 
release from protein kinase C as the common event during activation 
by lipid second messenger or reactive oxygen, J Biol Chem 277 (2002) 
44327-31. 
[135] D.W. Busija, P. Katakam, N.C. Rajapakse, B. Kis, G. Grover, F. 
Domoki and F. Bari, Effects of ATP-sensitive potassium channel 
activators diazoxide and BMS-191095 on membrane potential and 
reactive oxygen species production in isolated piglet mitochondria, 
Brain Res Bull 66 (2005) 85-90. 
67 
